芦可替尼治疗骨髓纤维化的疗效与安全性

打开文本图片集

中图分类号R559；R969.3 文献标志码A 文章编号 1001-0408（2025）14-1781-05

DOI 10.6039/j.issn.1001-0408.2025.14.16

ABSTRACTOBJECTIVETo explore the eficacyand safetyof ruxolib in the treatmentof myelofibrosis （MF）.METHODS Aretrospectivecollctionofdata wasconductedon42MFpatients whoweretreated withruxolitibinastandardized manerfor morethan6monthsintheThirdPeople'sHospitalofBengbufromSeptember2018toApril2024.Theclinicalsymptomscores， spleensizereduction，andMFgradingof thepatientsbeforeandaftertreatment wereanalyzed.Addionally，theoccurrenceof adverse reactions withacausalityassessmentresultof“definite”“probable”or“posible”wasrecorded.Thepatients’survival status was follwedup.RESULTS After6monthsof reatment，both clinicalsymptomscoresandthetotalscore weresignificantly decreased than before treatment （ ⋅P<0.05 ）.The length and thickness of the spleen were significantly shorter than before treatment （ ⋅<0.05 ）.MFclasificationin5patients decreasedby1levelcompared with baseline，1casewas level2and droppedto level0， 14patientsremained stable.Themainadversereactionswereanemia（26cases），thrombocytopenia（14cases），infection（11 cases），and gastrointestinal discomfort （9 cases）.Thirty-nine patients survived，with a survival rate of 92.86% .CONCLUSIONS RuxolitinibcanefectivelyimprovetheclinicalsymptomsofpatientswithMF，shrinkthesplee，stabilizeandevenimproveMF grading，andholdspromiseforbringinglong-termsurvivalbenefitstoMFpatients.Adversereactionsaremainlyanemia， thrombocytopenia，infection and gastrointestinal discomfort.

KEYWORDSruxolitinib；myelofibrosis；efficacy；safety

经典型骨髓增殖性肿瘤（myeloproliferativeneo-plasms，MPNs）是一组由造血干细胞克隆性增殖引起的疾病，包括原发性骨髓纤维化（primarymyelofibrosis，PMF）、原发性血小板增多症（essentialthrombocythemia，ET）和真性红细胞增多症（polycythemiavera，PV）[]。（剩余10568字）